FDA
approval
· 2022-09-30
FDA Approved: RYALTRIS — Supplemental Application (HIKMA SPECIALTY USA INC.)
Summary
The FDA approved a supplemental application for RYALTRIS, a combination nasal spray of olopatadine hydrochloride and mometasone furoate, submitted by Hikma Spec…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)